查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2016884

经导管肺动脉瓣膜市场：按瓣膜类型、应用和最终用户划分－2026-2032年全球市场预测

Transcatheter Pulmonary Valve Market by Valve Type, Application, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 193 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，经导管肺动脉瓣膜市场价值将达到 7,620 万美元，到 2026 年将成长至 8,559 万美元，到 2032 年将达到 1.422 亿美元，年复合成长率为 9.32%。

主要市场统计数据
基准年 2025 7620万美元
预计年份：2026年 8559万美元
预测年份 2032 1.422亿美元
复合年增长率 (%) 9.32%

全面介绍经导管肺动脉瓣治疗，重点在于临床进展、手术的广泛应用以及对相关人员的策略意义。

经导管肺动脉瓣置换术已从一项实验性干预发展成为一项临床有效的治疗选择，满足了先天性和后天性右心室流出道功能障碍患者的重大未满足医疗需求。经皮瓣膜置换系统的引入使临床医生能够为先天性疾病儿童和成人患者提供一种微创的替代开胸手术方案，从而减少手术全期併发症并缩短康復时间。技术的改进、影像技术的进步以及对患者选择标准的更深入理解，共同提升了治疗效果，并扩大了经导管肺动脉瓣置换术的临床适应症。

对正在重塑肺动脉瓣膜治疗和医疗保健服务策略的突破性技术、临床和营运变革进行权威性综述。

肺动脉瓣膜治疗领域正经历着一场变革性的转变，这主要得益于技术、临床和操作等多方面趋势的共同推动。瓣膜设计的进步，包括改进的径向力分布、组织工程以及输送系统柔软性，正在扩大瓣膜的解剖学适用范围，并降低手术入路带来的挑战。先进的影像技术和整合式引导平台能够实现瓣膜在复杂的右心室流出道内的精准定位和尺寸选择，从而降低併发症率，并增强临床医生在以往风险较高的解剖结构中进行手术的信心。

对 2025 年美国关税变化将如何重塑心臟设备产业的供应链、采购经济和战略製造决策进行清晰分析。

美国将于2025年实施的新关税措施，为医疗设备製造商和医疗服务提供者提供了重新评估其供应链、采购和定价策略的具体观点。对进口零件和组装设备的关税正在影响采购经济，迫使製造商探索本地生产、近岸外包以及其他替代采购方式，以维持利润率并为医院采购商提供具有竞争力的价格。这些贸易保护主义措施可能会增加依赖全球供应链网路的组织的前置作业时间和交易成本，进一步凸显了多元化采购和库存缓衝的必要性。

我们从策略角度分析医疗设备、临床环境和最终用户的细分，以确定产品功能和病患需求的交汇点，从而塑造商业性和临床路径。

详细的市场细分框架揭示了临床需求、产品差异化和终端用户行为如何相互作用，从而影响市场策略。根据瓣膜类型，市场主要分为两种器械类型：球囊扩张型式和自扩张式。球囊扩张型瓣膜包括成熟的平台，例如 Melody 瓣膜和 Sapien 经导管瓣膜，这些瓣膜已在特定尺寸和导管解剖结构中展现出效用。自扩张式瓣膜则以 Harmony 经导管肺动脉瓣膜和 Venus P 瓣膜等技术为代表，这些技术具有良好的适应性和径向适应性，适用于更宽且通常不规则的右心室流出道。这些瓣膜类型之间的技术权衡会影响各医疗机构的临床选择标准、库存管理和训练需求。

简要的区域概述，比较主要全球区域的采用趋势、法规环境和商业化路径。

区域趋势在塑造市场准入、监管路径和商业性实施方面发挥核心作用。在美洲，成熟的高绩效医疗中心和完善的介入性心臟病学生态系统，以及强大的临床网络和完善的医疗保险报销机制，为先进经导管肺动脉瓣膜解决方案的早期应用创造了有利环境。该地区的高手术量、集中的专业技术和活跃的临床研究群体，为市场准入和扩张提供了有力支持，这些优势能够产生上市后的安全性和疗效数据。

对塑造肺动脉瓣膜治疗领域公司差异化的竞争定位、合作策略和创新重点领域进行了清晰的概述。

经导管肺动脉瓣膜市场的竞争格局既有成熟的循环系统製造商，也有灵活敏捷、专注于创新的创新企业。主要企业优先考虑一种平衡的策略，将器材研发、临床证据产生和医疗专业人员培训相结合。器械製造商与先进影像公司之间的合作日益普遍，从而能够实现更可靠的术前规划和术中指导。与契约製造製造商和材料科学公司的策略合作也增强了生产的扩充性和组件品管。

为临床、製造和商业领域的领导者提供实用建议，以加快部署速度，确保供应弹性，并展现差异化的临床价值。

产业领导者应采取积极主动的策略，协调临床、商业和营运方面的优先事项，以实现经导管肺动脉瓣膜治疗的长期价值。应投资于产生严谨的上市后证据，包括基于註册研究的结果和真实世界绩效指标，并为保险公司和转诊机构建立引人入胜的临床案例。将这种与临床数据的互动与模组化训练计画和使用模拟技术的指导医师训练相结合，可以在确保病人安全和手术结果一致性的同时，加速该技术的推广应用。

透明、多方面的研究途径，结合临床访谈、监管审查、供应链分析和资料三角验证，确保获得可靠、可操作的见解。

本报告的研究结合了质性研究、严谨的第二手资料整合以及结构化资料检验。主要调查方法包括对介入性心臟病专家、先天性心臟疾病专家、采购经理和行业高管进行深度访谈，以获取关于器械选择、手术流程和推广障碍的第一手资讯。除访谈外，还对同行评审的临床文献、监管核准、临床註册摘要和器械特定安全资讯进行了结构化审查，以确保与最新的临床证据和安全信号保持一致。

简洁扼要的结论强调，临床证据、供应弹性和策略商业化是永续推广和对病人产生影响的先决条件。

经导管肺动脉瓣膜治疗正处于转折点，只有透过技术创新、临床证据和策略商业化三者之间的和谐平衡，才能实现患者的持续获益并确立治疗方法。瓣膜设计的改进、先进的影像技术以及不断发展的治疗模式正在拓展经皮肺动脉瓣置换术的临床应用潜力。然而，供应链的韧性、价格压力以及对可靠真实世界数据（REW）的需求等营运挑战，仍然是影响治疗方法普及率和公平性的关键因素。

目录

第一章：序言

第二章：调查方法

  • 调查设计
  • 研究框架
  • 市场规模预测
  • 数据三角测量
  • 调查结果
  • 调查的前提
  • 研究限制

第三章执行摘要

  • 首席主管观点
  • 市场规模和成长趋势
  • 2025年市占率分析
  • FPNV定位矩阵，2025
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 上市策略

第五章 市场洞察

  • 消费者洞察与终端用户观点
  • 消费者体验基准
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 投资报酬率和成本效益分析

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

第八章 经导管肺动脉瓣膜类型

  • 球囊扩张型阀
    • 旋律阀
    • Sapien经导管瓣膜
  • 自膨胀阀
    • Harmony经导管肺动脉瓣膜
    • 金星P瓣膜

第九章 经导管肺动脉瓣膜市场：依应用领域划分

  • 复杂病变
  • 肺动脉逆流
  • 肺动脉狭窄

第十章 经导管肺动脉瓣膜市场：依最终用户划分

  • 门诊手术中心
  • 心臟中心
  • 医院

第十一章 经导管肺动脉瓣膜市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十二章 经导管肺动脉瓣膜市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十三章 经导管肺动脉瓣膜市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十四章：美国经导管肺动脉瓣膜市场

第十五章：中国经导管肺动脉瓣膜市场

第十六章 竞争格局

  • 市场集中度分析，2025年
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析，2025 年
  • 2025年产品系列分析
  • 基准分析，2025 年
  • Braile Biomedica
  • Jude Medical Inc
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Lifetech Scientific Corporation
  • LivaNova Plc
  • Medtronic plc
  • MicroPort Scientific Corporation
  • TaeWoong Medical Industrial Co., Ltd.
  • Umbra Valve Technologies BV
  • Venus MedTech（Hangzhou）Co., Ltd.
  • Xeltis SA
Product Code: MRR-03168519576D

The Transcatheter Pulmonary Valve Market was valued at USD 76.20 million in 2025 and is projected to grow to USD 85.59 million in 2026, with a CAGR of 9.32%, reaching USD 142.20 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 76.20 million
Estimated Year [2026] USD 85.59 million
Forecast Year [2032] USD 142.20 million
CAGR (%) 9.32%

A comprehensive introduction to transcatheter pulmonary valve therapy highlighting clinical evolution, procedural adoption, and strategic implications for stakeholders

Transcatheter pulmonary valve therapy has transitioned from an experimental intervention into a clinically viable option that addresses significant unmet needs among patients with congenital and acquired right ventricular outflow tract dysfunction. The introduction of percutaneous valve systems has enabled clinicians to offer less invasive alternatives to repeat open-heart surgery, reducing perioperative morbidity and shortening recovery pathways for both pediatric and adult congenital populations. Procedural refinements, imaging advances, and a deeper understanding of patient selection criteria have collectively strengthened outcomes and expanded the clinical indications for catheter-based pulmonary valve replacement.

Clinical practice now emphasizes heart-team collaboration that integrates congenital cardiologists, interventionalists, cardiac surgeons, and advanced imaging specialists. This multidisciplinary approach optimizes device selection, access strategy, and post-procedural surveillance. As operators accumulate procedural experience and centers codify pathways for patient follow-up, safety profiles have improved while the threshold for treating symptomatic and asymptomatic lesions has evolved. Regulatory clearances and real-world registry data have further legitimized transcatheter pulmonary valve interventions, fostering broader adoption across tertiary referral centers and select ambulatory surgical settings.

From a strategic perspective, device manufacturers, health systems, and clinical investigators are positioned to translate technical advances into scalable care models. The pathway forward requires coordinated investments in training, post-market evidence generation, and supply chain resilience to ensure equitable access and consistent procedural performance across geographies and provider types.

An authoritative synthesis of the transformative technological, clinical, and operational shifts reshaping pulmonary valve therapy and provider strategy

The landscape for pulmonary valve therapies is undergoing transformative shifts driven by converging technological, clinical, and operational dynamics. Advances in valve design, including improvements in radial force profiles, tissue engineering, and delivery-system flexibility, are expanding anatomical applicability and reducing access-related challenges. Enhanced imaging modalities and fusion-guidance platforms enable precise positioning and sizing in complex right ventricular outflow tracts, lowering complication rates and expanding operator confidence in anatomies previously deemed high risk.

Concurrently, a shift in clinical paradigms has emerged as long-term valve durability and patient quality of life become central endpoints. Innovations in device retrievability and modular approaches support staged procedures and tailored therapies for diverse patient cohorts. Regulatory ecosystems are adapting to hybrid evidence models that combine randomized data with high-quality registries, accelerating conditional approvals in regions where unmet need is highest. Reimbursement conversations are likewise evolving, with payers increasingly attentive to value-based metrics such as reduced readmissions, shorter length of stay, and long-term functional improvement.

Operationally, centers of excellence are forming to concentrate expertise and streamline patient pathways, while partnerships between device developers and imaging firms are integrating predictive planning tools. As a result, the competitive landscape is shifting from single-product strategies to integrated solutions that bundle devices, imaging protocols, and clinical training, thereby redefining what it means to deliver high-value transcatheter pulmonary care.

A clear analysis of how the 2025 United States tariff changes are reshaping supply chains, procurement economics, and strategic manufacturing decisions in cardiac device sectors

The implementation of new tariff measures in the United States in 2025 has introduced a tangible lens through which device manufacturers and health providers are re-evaluating supply chain, procurement, and pricing strategies. Tariffs on imported components and assembled devices affect procurement economics, prompting manufacturers to assess localized production, nearshoring options, and alternative sourcing to preserve margin and maintain competitive pricing for hospital purchasers. These protective trade measures can increase lead times and transactional costs for organizations reliant on global supply networks, reinforcing the need for multi-sourcing and inventory buffers.

Clinical programs and hospital purchasers face the prospect of negotiating revised contract terms that account for import-related surcharges and potential variability in device availability. Health systems must balance the imperative of cost containment with clinical imperatives that prioritize patient outcomes; this often necessitates transparent dialogues between clinical leaders and procurement teams to align on acceptable trade-offs and priority access for high-risk patients. In parallel, manufacturers are accelerating efforts to diversify component suppliers, qualify domestic vendors, and invest in automated manufacturing to offset tariff-driven cost pressures.

Policy responses and procurement strategies will ultimately determine the extent to which tariffs alter device adoption trajectories. Stakeholders that proactively model tariff sensitivities, secure contingency manufacturing capacity, and communicate clinical value compellingly to payers and health system buyers will most effectively mitigate the operational disruptions introduced in 2025. This adaptive posture reduces risk to patients and preserves momentum for innovation and broader clinical adoption.

A strategic breakdown of device, clinical, and end-user segmentation revealing where product features and patient needs intersect to shape commercial and clinical pathways

A granular segmentation framework illuminates where clinical demand, product differentiation, and end-user behavior intersect to shape strategy. Based on valve type, the landscape is characterized by two dominant device approaches: balloon expandable designs and self-expanding systems. Balloon expandable valves include well-established platforms such as the Melody valve and the Sapien transcatheter valve, which have proven utility in specific valve sizes and conduit anatomies. Self-expanding systems are represented by technologies like the Harmony transcatheter pulmonary valve and the Venus P-Valve, which offer conformability and radial adaptation suited to broader and often irregular right ventricular outflow tracts. The technical trade-offs between these valve types inform clinical selection criteria, inventory management, and training requirements across centers.

Application-based segmentation further refines clinical pathways and evidence needs. Patient presentations span combined lesions, pulmonary regurgitation, and pulmonary stenosis, each with distinct hemodynamic considerations and procedural planning imperatives. Devices compatible with mixed pathology must demonstrate versatility in sealing, anchoring, and hemodynamic performance, while those intended primarily for stenosis or regurgitation can optimize for low-profile delivery or enhanced radial support, respectively. End-user segmentation underscores where adoption manifests operationally: ambulatory surgical centers, cardiac centers, and hospitals each have unique infrastructure, case mix, and purchasing models. Ambulatory surgical centers may prioritize throughput and same-day discharge protocols, cardiac centers focus on complex cases and multidisciplinary pathways, and hospitals balance acute care capacity with broader inpatient capabilities.

Understanding how valve type, clinical application, and end-user environment interact enables manufacturers and providers to align product portfolios, training programs, and commercialization plans with the practical realities of device deployment and outcomes monitoring.

A concise regional intelligence overview that contrasts adoption dynamics, regulatory environments, and commercialization pathways across key global territories

Regional dynamics play a central role in shaping access, regulatory pathways, and commercial execution. In the Americas, established centers of excellence and a mature interventional cardiology ecosystem create a favorable environment for early adoption of advanced transcatheter pulmonary solutions, supported by robust clinical networks and well-developed reimbursement frameworks. Market entry and scale-up efforts in this region benefit from high procedural volumes, concentrated specialist expertise, and active clinical research communities that generate post-market safety and performance data.

The Europe, Middle East & Africa region presents a heterogeneous landscape where regulatory diversity, variable reimbursement pathways, and disparate infrastructure influence adoption rates. Western European markets typically demonstrate rapid uptake when clinical evidence supports improved outcomes, whereas emerging markets in the broader EMR and African corridors prioritize cost-effective solutions and resilient supply chains. Strategic partners in these geographies often require tailored pricing, capacity-building programs, and local evidence generation to facilitate uptake.

Asia-Pacific exhibits accelerated investment in congenital and structural heart disease programs alongside a strategic emphasis on domestic manufacturing and innovation hubs. Several countries in this region are scaling specialized cardiac centers and driving localized clinical registries that inform device adaptation for population-specific anatomies. Cross-border collaboration and technology transfer initiatives are increasingly common as manufacturers navigate regulatory pathways and local clinical expectations.

An incisive overview of competitive positioning, alliance strategies, and innovation focus areas shaping company-level differentiation in pulmonary valve therapies

The competitive environment in transcatheter pulmonary valves reflects a mix of established cardiovascular device manufacturers and agile specialized innovators. Leading organizations prioritize a balanced approach that couples device engineering with clinical evidence generation and provider education. Partnerships between device makers and advanced imaging firms are becoming commonplace, enabling more reliable pre-procedure planning and intra-procedural guidance. Strategic collaborations with contract manufacturers and material science firms also enhance manufacturing scalability and component quality control.

Innovation pipelines emphasize durability, deliverability, and adaptability to challenging anatomies, with an increasing number of entrants exploring tissue treatments and anti-calcification technologies to extend valve longevity. Commercial strategies focus on bundled service offerings that include proctoring, simulation training, and outcomes support to reduce the learning curve for new adopters. In parallel, some companies are pursuing targeted geographic expansion through local distributors and clinical partnerships, while others invest in direct-market presence where regulatory and reimbursement conditions favor premium positioning.

Mergers, acquisitions, and licensing agreements continue to be strategic levers for achieving category leadership, particularly where complementary imaging, supply chain, or reimbursement expertise can be integrated. Organizations that align robust clinical programs with scalable manufacturing and clear value messaging are best positioned to capture sustained clinical traction and institutional adoption.

Actionable recommendations for clinical, manufacturing, and commercial leaders to accelerate adoption, secure supply resilience, and demonstrate differentiated clinical value

Industry leaders should pursue a proactive strategy that aligns clinical, commercial, and operational priorities to capture long-term value in transcatheter pulmonary valve care. Invest in rigorous post-market evidence generation that includes registry-based outcomes and real-world performance metrics to build a compelling clinical narrative for payers and referral centers. Combine these clinical data efforts with modular training programs and simulation-based proctoring to accelerate adoption while maintaining patient safety and consistent procedural outcomes.

From an operational standpoint, diversify component sourcing and pursue nearshoring where feasible to mitigate tariff exposure and ensure continuity of supply. Engage early with regulatory bodies to clarify pathways for incremental device enhancements and to design adaptive evidence plans that leverage both prospective cohorts and pragmatic registry data. On the commercial front, craft value propositions tailored to end-user segments: emphasize throughput and cost-efficiency for ambulatory surgical facilities, advanced case support and multidisciplinary partnerships for cardiac centers, and comprehensive perioperative care bundles for hospitals.

Finally, pursue strategic collaborations with imaging and digital-health providers to deliver integrated planning tools that reduce procedural variability. Prioritize transparent pricing models and outcomes-linked contracting to align incentives with health systems and payers, thereby supporting broader access while protecting margin and ensuring sustainable growth.

A transparent, multi-method research approach combining clinical interviews, regulatory review, supply-chain analysis, and data triangulation to ensure robust, actionable insights

The research underpinning this report blends primary qualitative engagement with rigorous secondary synthesis and structured data validation. Primary methods included in-depth interviews with interventional cardiologists, congenital heart surgeons, procurement leaders, and industry executives to capture experiential insights on device selection, procedural workflows, and adoption barriers. These conversations were complemented by structured reviews of peer-reviewed clinical literature, regulatory approvals, clinical registry summaries, and device-specific safety communications to ensure alignment with the latest clinical evidence and safety signals.

Data triangulation was applied to reconcile discrepancies between field interviews, clinical reports, and public regulatory documentation, with a focus on reproducibility and source transparency. Manufacturing and supply-chain assessments utilized component mapping, supplier interviews, and publicly available trade data to identify critical nodes of risk and potential mitigation pathways. The analytical framework incorporated thematic coding of qualitative input, scenario analysis for policy and tariff impacts, and comparative device feature matrices to surface differentiators.

Quality assurance included multi-level peer review by clinical and market analysts, verification of primary source citations, and sensitivity checks to ensure conclusions remain robust given variations in regional practice patterns and regulatory timelines. Limitations are acknowledged, including variability in clinical reporting standards across registries and evolving policy environments that may alter procurement and reimbursement dynamics over time.

A concise conclusion emphasizing the alignment of clinical evidence, supply resilience, and strategic commercialization as prerequisites for sustainable adoption and patient impact

Transcatheter pulmonary valve therapy stands at an inflection point where technical innovation, clinical evidence, and strategic commercialization must align to achieve durable patient benefit and sustainable adoption. The confluence of improved valve designs, advanced imaging, and evolving treatment paradigms has expanded the clinical promise of percutaneous pulmonary valve replacement. However, operational challenges such as supply-chain resilience, tariff pressures, and the need for convincing real-world evidence remain critical determinants of the pace and equity of adoption.

For stakeholders crafting strategy in this space, the imperative is clear: invest in durable clinical evidence, secure diversified manufacturing footprints, and tailor commercialization approaches to the specific needs of ambulatory centers, cardiac specialty programs, and hospital systems. Organizations that integrate these elements with flexible pricing frameworks and comprehensive training will be best placed to convert clinical promise into consistent patient access and long-term value creation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Transcatheter Pulmonary Valve Market, by Valve Type

  • 8.1. Balloon Expandable Valve
    • 8.1.1. Melody Valve
    • 8.1.2. Sapien Transcatheter Valve
  • 8.2. Self Expanding Valve
    • 8.2.1. Harmony Transcatheter Pulmonary Valve
    • 8.2.2. Venus P-Valve

9. Transcatheter Pulmonary Valve Market, by Application

  • 9.1. Combined Lesions
  • 9.2. Pulmonary Regurgitation
  • 9.3. Pulmonary Stenosis

10. Transcatheter Pulmonary Valve Market, by End User

  • 10.1. Ambulatory Surgical Centers
  • 10.2. Cardiac Centers
  • 10.3. Hospitals

11. Transcatheter Pulmonary Valve Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Transcatheter Pulmonary Valve Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Transcatheter Pulmonary Valve Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Transcatheter Pulmonary Valve Market

15. China Transcatheter Pulmonary Valve Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Braile Biomedica
  • 16.6. Jude Medical Inc
  • 16.7. Lepu Medical Technology (Beijing) Co., Ltd.
  • 16.8. Lifetech Scientific Corporation
  • 16.9. LivaNova Plc
  • 16.10. Medtronic plc
  • 16.11. MicroPort Scientific Corporation
  • 16.12. TaeWoong Medical Industrial Co., Ltd.
  • 16.13. Umbra Valve Technologies B.V.
  • 16.14. Venus MedTech (Hangzhou) Co., Ltd.
  • 16.15. Xeltis SA

LIST OF FIGURES

  • FIGURE 1. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY MELODY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SAPIEN TRANSCATHETER VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HARMONY TRANSCATHETER PULMONARY VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VENUS P-VALVE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COMBINED LESIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY REGURGITATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY PULMONARY STENOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY CARDIAC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 44. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 45. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 46. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 47. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 48. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 49. AMERICAS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 50. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 52. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 53. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 54. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 55. NORTH AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 56. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 58. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 59. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 60. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 61. LATIN AMERICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 62. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 63. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 65. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 66. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 67. EUROPE, MIDDLE EAST & AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 69. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 70. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 71. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 72. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 73. EUROPE TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 74. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 75. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 76. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 77. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 78. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 79. MIDDLE EAST TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 80. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 82. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 83. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 84. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 85. AFRICA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 89. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 90. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 91. ASIA-PACIFIC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 93. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 96. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 97. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 98. ASEAN TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 99. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 100. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 101. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 102. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 103. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 104. GCC TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 105. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 106. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 107. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 108. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 109. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 110. EUROPEAN UNION TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 111. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 113. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 114. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 115. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 116. BRICS TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 117. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 118. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 119. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 120. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 121. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 122. G7 TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 123. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 124. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 125. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 126. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 127. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 128. NATO TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 130. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 131. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 132. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 133. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 134. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 135. UNITED STATES TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 136. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 137. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY VALVE TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY BALLOON EXPANDABLE VALVE, 2018-2032 (USD MILLION)
  • TABLE 139. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY SELF EXPANDING VALVE, 2018-2032 (USD MILLION)
  • TABLE 140. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 141. CHINA TRANSCATHETER PULMONARY VALVE MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)